Enhancing innate immunity in the lung
Sep. 12, 2022—Vanderbilt researchers show that a TLR4 agonist improves lung immune response and survival in a mouse model of bacterial pneumonia, supporting the development of this drug to protect against pneumonia in hospitalized patients.
CRISPR screen identifies new anti-inflammatory drug target
Nov. 11, 2021—A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.
Rational vaccine design
Sep. 22, 2020—Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.
Antibody mixture may help block Ebola virus infection
Feb. 6, 2020—A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
RNA processing and antiviral immunity
Dec. 13, 2018—John Karijolich and colleagues have discovered a link between cellular RNA processing and the innate cellular immune response to viral pathogens.
Team finds potent antibodies against three Ebola viruses
Jul. 19, 2018—Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans.
Immune cells that guard against ingested pathogens discovered
Oct. 9, 2014—Vanderbilt investigators have discovered a new type of immune cell residing in the intestinal epithelium that may function as a first line of defense against ingested pathogens.